BORYUNG CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,930 KRW | -0.18% |
|
-1.09% | -8.07% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- With a P/E ratio at 11.36 for the current year and 9.44 for next year, earnings multiples are highly attractive compared with competitors.
- With regards to fundamentals, the enterprise value to sales ratio is at 691.1 for the current period. Therefore, the company is undervalued.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.07% | 527M | - | ||
| +19.62% | 43.34B | B- | ||
| +20.44% | 21.96B | B+ | ||
| +10.86% | 14.09B | - | ||
| +13.07% | 13.64B | B+ | ||
| +37.46% | 11.43B | B | ||
| -8.59% | 6.86B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +8.46% | 5.22B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A003850 Stock
- Ratings Boryung Corporation
